Key result
Loss-of-function variants in ANGPTL3 are associated with familial combined hypolipidemia, characterized by marked reduction of all plasma lipoproteins.
Population
Individuals with loss-of-function variants in ANGPTL3 showing familial combined hypolipidemia
Design
Review
Authors
Loading...
Supports ANGPTL3 as therapeutic target; leaves open cardiovascular benefit confirmation in randomized trials.
ANGPTL3 is identified as a key regulator of lipid and glucose metabolism, making it a promising therapeutic target for reducing cardio-metabolic risk.
Arca et al. (2013) conducted a review in Familial combined hypolipidemia. ANGPTL3 loss-of-function variants was evaluated. Loss-of-function variants in ANGPTL3 are associated with familial combined hypolipidemia, characterized by marked reduction of all plasma lipoproteins.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: